Ajay K. Singh, MBBS, FRCP, MBA

Articles by Ajay K. Singh, MBBS, FRCP, MBA

Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | November 13, 2023
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Read More
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | October 26, 2023
The first part of the dialysis moonshot is to prevent the need for dialysis.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | September 18, 2023
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 9, 2023
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | December 22, 2020
Editor's Note: ...